| Grenier, Julien |
| Recruiting | 3 | 400 | Europe | Palbociclib 125mg, Ibrance, PD-0332991, Standard endocrine therapy | ETOP IBCSG Partners Foundation, Pfizer | Breast Cancer Recurrent | 01/25 | 11/27 | | |
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery |
|
|
| Recruiting | 3 | 250 | Europe, Japan | Carboplatin, Paclitaxel | ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission | Ovarian Cancer | 06/27 | 06/28 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
| Recruiting | 3 | 260 | Europe, Canada, Japan, RoW | Carboplatin-Paclitaxel, Dostarlimab | ARCAGY/ GINECO GROUP, GlaxoSmithKline | Endometrial Cancer | 04/26 | 10/29 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Active, not recruiting | 2 | 52 | Europe | Pembrolizumab Injection, MK3475, neoadjuvant EC-paclitaxel chemotherapy, Epirubicine, Cyclophosphamide, Paclitaxel | Institut Paoli-Calmettes, MSD France, Oncodistinct | Inflammatory Breast Cancer | 08/22 | 08/27 | | |
| Recruiting | 2 | 390 | Europe, Japan, RoW | Chemotherapy, Bevacizumab-Awwb, Niraparib | ARCAGY/ GINECO GROUP, GSK | Ovarian Cancer | 02/27 | 02/30 | | |
| Recruiting | 2 | 90 | Europe | Trastuzumab + Paclitaxel, Pegfilgrastim, Neulasta | Centre Leon Berard, Amgen | HER2-positive Breast Cancer, Operable Breast Cancer | 01/25 | 09/25 | | |
| Active, not recruiting | 2 | 53 | Europe | Tucatinib, Pertuzumab, Perjeta®, Trastuzumab, Herceptin® or Biosimilar, Hormone therapy, Pertuzumab/ Trastuzumab, Phesgo® | UNICANCER, Seagen Inc., ARCAGY/ GINECO GROUP | Metastatic Breast Cancer With a Isolated Brain Progression | 04/25 | 04/26 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
TUC-TOC, NCT05955170: Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer |
|
|
| Recruiting | 2 | 66 | Europe | Tucatinib in Combination of Oral VP16 and trastuzumab | Institut Curie, Seagen Inc. | HER2-positive Breast Cancer | 12/26 | 12/27 | | |
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade |
|
|
| Terminated | 2 | 139 | Europe, RoW | Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1 | Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie | HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer | 11/24 | 11/24 | | |
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer |
|
|
| Recruiting | 2 | 1100 | Europe | Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole | Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation | ER+ Breast Cancer, HER2-negative Breast Cancer | 09/27 | 09/30 | | |
| Recruiting | 2 | 1100 | Europe | Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant) | SOLTI Breast Cancer Research Group, Novartis, UNICANCER | Breast Cancer Stage II | 08/28 | 07/30 | | |
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC |
|
|
| Recruiting | 2 | 354 | Europe | Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol | UNICANCER, MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca | Triple-negative Breast Cancer | 12/31 | 12/31 | | |
KELI-PAOLA, NCT06660147: Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer |
|
|
| Recruiting | N/A | 327 | Europe, RoW | | ARCAGY/ GINECO GROUP | Ovarian Cancer | 12/24 | 12/24 | | |
FEGALA, NCT06379880: Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution |
|
|
| Recruiting | N/A | 506 | Europe | CONTINUUM+ CONNECT remote monitoring | Institut de cancérologie Strasbourg Europe, Continuum Plus Santé, Plateforme nationale qualité de vie et cancer, WeShare | Prostatic Neoplasms, Lung Neoplasms, Breast Neoplasms, Colorectal Neoplasms | 11/24 | 02/25 | | |
ABLE02, NCT04354233: A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 244 | Europe | Physical activity intervention with connected devices | Centre Leon Berard, Fondation ARC, Janssen, LP | Metastatic Breast Cancer | 06/24 | 06/25 | | |
| Not yet recruiting | N/A | 450 | Europe | ctDNA monitoring, 68Ga-FAPI-46-PET-CT | Institut Curie, National Research Agency, France, Roche Pharma AG | Triple Negative Breast Cancer | 12/26 | 12/28 | | |
LARENA, NCT06599463: Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study |
|
|
| Recruiting | N/A | 250 | Europe | | ARCAGY/ GINECO GROUP, Institut Curie | Metastatic Endometrial Cancer | 12/24 | 12/24 | | |
| Grellety, Thomas |
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
|
|
| Active, not recruiting | 3 | 866 | Europe, Japan, US, RoW | Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219 | Eli Lilly and Company, Eli Lilly and Company | Breast Neoplasms, Neoplasm Metastasis | 06/24 | 08/27 | | |
SALVOVAR, NCT06476184: Utility of Adjusting Chemotherapy Dose & Dosing Schedule with the SALVage Weekly Dose-dense Regimen in Patients with Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery |
|
|
| Recruiting | 3 | 250 | Europe, Japan | Carboplatin, Paclitaxel | ARCAGY/ GINECO GROUP, Horizon 2020 - European Commission | Ovarian Cancer | 06/27 | 06/28 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
| Recruiting | 3 | 220 | Europe | Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG | European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group | ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer | 07/28 | 05/30 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
MegaMOST, NCT04116541: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/characteristics in Advanced / Metastatic Tumors. |
|
|
| Recruiting | 2 | 455 | Europe | HDM201, Closed cohort, Ribociclib, Cabozantinib, Open cohort, Alectinib, Regorafenib, Trametinib, Dabrafenib, Avapritinib | Centre Leon Berard | Malignant Solid Tumor | 02/26 | 11/26 | | |
Decrescendo, NCT04675827: De-escalation Adjuvant Chemo in HER2+/ER-/node-neg Early BC Patients Who Achieved PCR After Neoadjuvant Chemo & Dual HER2 Blockade |
|
|
| Terminated | 2 | 139 | Europe, RoW | Pertuzumab and tratuzumab fixed dose combination, Adjuvant pertuzumab + trastuzumab FDC SC for 14 cycles, Fixed-dose combination of Perjeta and Herceptin for subcutaneous injection for 14 cycles, Trastuzumab emtansine, Adjuvant T-DM1 | Jules Bordet Institute, Breast International Group, Hoffmann-La Roche, International Drug Development Institute, Institut Curie | HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer, Node-negative Breast Cancer | 11/24 | 11/24 | | |
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib |
|
|
| Recruiting | 2 | 162 | Europe | Alpelisib, Fulvestrant, Ribociclib | UNICANCER, Novartis, Breast Cancer Research Foundation | Breast Cancer Stage IV | 07/28 | 06/30 | | |
| Recruiting | 2 | 1100 | Europe | Ribociclib (neoadjuvant), Kisqali, Chemotherapy (adjuvant), Ribociclib (adjuvant) | SOLTI Breast Cancer Research Group, Novartis, UNICANCER | Breast Cancer Stage II | 08/28 | 07/30 | | |
ETNA, NCT06078384: Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC |
|
|
| Recruiting | 2 | 354 | Europe | Pembrolizumab 25 mg/ml, keytruda, Paclitaxel injection, Taxol | UNICANCER, MSD France, SOLTI Breast Cancer Research Group, Gustave Roussy, Cancer Campus, Grand Paris, Vall Hebron Insitut Recerca | Triple-negative Breast Cancer | 12/31 | 12/31 | | |
| Recruiting | N/A | 1500 | Europe, RoW | biopsy liquid | Gustave Roussy, Cancer Campus, Grand Paris, Roche Pharma AG | Metastatic Cancer | 11/24 | 04/25 | | |
COPE, NCT04258137: Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study |
|
|
| Recruiting | N/A | 332 | Europe | Liquid biopsy | Institut Bergonié | Colorectal Cancer, Non Small Cell Lung Cancer | 09/24 | 04/25 | | |
BIP, NCT02534649: Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials |
|
|
| Recruiting | N/A | 10000 | Europe | Newly obtained biopsy and Blood samples collection | Institut Bergonié | Solid Tumor, Hematological Malignancy | 03/28 | 12/29 | | |
| BILLEMONT, Bertrand |
| Recruiting | 3 | 1250 | Europe, RoW | Nivolumab, OPDIVO, Ipilimumab, YERVOY, Pembrolizumab, KEYTRUDA, Cabozantinib, CABOMETYX, Axitinib, INLYTA, Lenvatinib, LENVIMA | Gustave Roussy, Cancer Campus, Grand Paris, European Commission, CRIS Cancer Foundation, National Cancer Institute, France, Rennes University Hospital, University Hospital, Essen, Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron, The Netherlands Cancer Institute, Servicio Madrileño de Salud, Madrid, Spain, Hospital Universitario 12 de Octubre, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Medical University of Vienna, FAKULTNI NEMOCNICE OLOMOUC, International Kidney Cancer Coalition, Association pour la Recherche sur les Tumeurs du Rein, Resilience, PRIMAA, Queen Mary University of London | Metastatic Kidney Cancer, Metastatic Kidney Carcinoma | 05/32 | 05/32 | | |
| Recruiting | 3 | 260 | Europe, Canada, Japan, RoW | Carboplatin-Paclitaxel, Dostarlimab | ARCAGY/ GINECO GROUP, GlaxoSmithKline | Endometrial Cancer | 04/26 | 10/29 | | |
COLIBRI-2, NCT06715241: A MULTICENTER, SEEKING SIGNAL, RANDOMISED, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB ALONE IN LOCALLY ADVANCED CERVICAL CANCERS |
|
|
| Recruiting | 2 | 77 | Europe | combination of relatlimab and nivolumab wich are two immunotherapy treatments, Nivolumab alone | ARCAGY/ GINECO GROUP | LOCALLY ADVANCED CERVICAL CANCERS | 12/30 | 12/30 | | |
SAFIR 03, NCT05625087: Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib |
|
|
| Recruiting | 2 | 162 | Europe | Alpelisib, Fulvestrant, Ribociclib | UNICANCER, Novartis, Breast Cancer Research Foundation | Breast Cancer Stage IV | 07/28 | 06/30 | | |
ABLE02, NCT04354233: A Physical Activity Program to Improve Quality of Life and Reduce Fatigue in Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 244 | Europe | Physical activity intervention with connected devices | Centre Leon Berard, Fondation ARC, Janssen, LP | Metastatic Breast Cancer | 06/24 | 06/25 | | |
